RecruitingPhase 1

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Mexico12 participantsStarted 2022-11-08

Plain-language summary

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age ≥ 18 years.
✓. Subject is phakic or pseudophakic with a posterior chamber intraocular lens (lens in the bag or sulcus).
✓. Symptomatic corneal edema associated with endothelial dysfunction which may be secondary to Fuchs' corneal dystrophy or pseudophakic bullous keratopathy.

✕. Other corneal disease
✕. Anterior chamber intraocular lens
✕. Sutured or scleral-fixated intraocular lens.
✕. Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
✕. History of refractive surgery.
✕. History of Vitrectomy
✕. Descemet membrane detachment.
✕. History of uveitis or other ocular inflammatory disease.

Safety and Tolerability of multiple doses of EO2002

Timeframe: 32 weeks

NCT IDNCT05636579

SponsorAsociación para Evitar la Ceguera en México

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-09

Yara Luna